Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selumetinib as a Target Therapy in Progressive Paediatric Low-Grade Gliomas-Case Series (pLGG).

Journal of paediatrics and child health·2026
Same author

Selumetinib in the treatment of plexiform neurofibromas in neurofibromatosis type 1: a 6-year prospective case series with review of the literature.

BMC pediatrics·2026
Same author

A mixed prebiotic/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case-control pilot study.

Breast (Edinburgh, Scotland)·2026
Same author

Budget impact analysis of Oncotype DX<sup>®</sup> multigenic prognostic test in patients with early breast cancer in Italy.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same author

The diversity of cytomegalovirus among blood donors and transplant recipients could affect the effectiveness of specific anti-CMV immunoglobulins.

Frontiers in immunology·2026
Same author

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

Breast (Edinburgh, Scotland)·2026

Related Experiment Video

Updated: Apr 6, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Ibrutinib: from bench side to clinical implications.

Davide Grisafi1, Alessandra Maestro, Camilla Grumi

  • 1Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Medical Oncology (Northwood, London, England)
|July 31, 2015
PubMed
Summary
This summary is machine-generated.

Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib are effective treatments for B cell malignancies. These drugs target key pathways, enhancing cancer cell survival and proliferation, offering new hope for patients.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • B cell receptor (BCR) activation is crucial in B cell malignancies, promoting cancer cell proliferation and survival.
  • Understanding BCR signaling pathways led to the development of targeted therapies.
  • Bruton's tyrosine kinase (BTK) is a key enzyme in BCR signaling.

Purpose of the Study:

  • To review the pharmacological evidence for ibrutinib, a BTK inhibitor.
  • To discuss the mechanism of action of ibrutinib in B cell malignancies.
  • To summarize the efficacy of ibrutinib in treating various B cell cancers.

Main Methods:

  • Literature review of pharmacological data on ibrutinib.
  • Analysis of studies investigating BTK inhibition in B cell malignancies.
  • Examination of clinical trial results and mechanism of action research.

Main Results:

  • Ibrutinib is a potent, specific, irreversible BTK inhibitor.
  • Demonstrated efficacy in chronic lymphocytic leukemia, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, Waldenström macroglobulinemia, and multiple myeloma.
  • Ibrutinib targets critical pathways involved in B cell proliferation and survival.

Conclusions:

  • Ibrutinib represents a significant advancement in treating B cell malignancies.
  • Targeting BTK offers a promising therapeutic strategy for these cancers.
  • Further research continues to elucidate the full potential and mechanisms of ibrutinib.